Vertex Pharmaceuticals Incorporated: One Eye on Earnings, One on the Pipeline
Vertex Pharmaceuticals (NASDAQ: VRTX) reported solid third-quarter earnings, with sales of its cystic fibrosis drugs up 34% year over year. Nevertheless, investors rightfully have one eye on the company's pipeline, looking for the next drug that will drive future growth. Fortunately, Vertex has a combination under review by U.S. and EU regulators, and is preparing to test a pair of triple combinations that the company thinks will allow it to treat 90% of cystic fibrosis patients.
Metric
Q3 2017
Source: Fool.com
Vertex Pharmaceuticals Inc. Stock
€433.75
-0.090%
The stock is one of the favorites of our community with 60 Buy predictions and 2 Sell predictions.
With a target price of 459 € there is a slightly positive potential of 5.82% for Vertex Pharmaceuticals Inc. compared to the current price of 433.75 €.
